A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer

被引：0
|
作者：
Munster, Pamela N.
Miller, Kathy
Krop, Ian E.
Dhindsa, Navreet
Reynolds, Joe
Geretti, Elena
Niyikiza, Clet
Nielsen, Ulrik
Hendriks, Bart
Wickham, Thomas J.
Moyo, Victor M.
LoRusso, Patricia
机构：
[1] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Merrimack Pharmaceut, Cambridge, MA USA
[5] Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS663
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
    Diogo Mendes
    Carlos Alves
    Noémia Afonso
    Fátima Cardoso
    José Luís Passos-Coelho
    Luís Costa
    Sofia Andrade
    Francisco Batel-Marques
    Breast Cancer Research, 17
  • [32] Efficacy of HER2-targeted therapy for patients with HER2-positive breast cancer according to hormone receptor status.
    Murata, Takeshi
    Takahashi, Maiko
    Hayashida, Tetsu
    Jinno, Hiromitsu
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [33] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review
    Mendes, Diogo
    Alves, Carlos
    Afonso, Noemia
    Cardoso, Fatima
    Passos-Coelho, Jose Luis
    Costa, Luis
    Andrade, Sofia
    Batel-Marques, Francisco
    BREAST CANCER RESEARCH, 2015, 17
  • [34] Tumor priming with cyclophosphamide for enhanced tumor delivery, penetration and anti-tumor activity of MM-302, HER2-targeted liposomal doxorubicin
    Geretti, Elena
    Leonard, Shannon C.
    Dumont, Nancy
    Espelin, Christopher W.
    Gaddy, Daniel F.
    Wickham, Thomas J.
    Hendriks, Bart S.
    CANCER RESEARCH, 2015, 75
  • [35] The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer
    Jiang, Lei
    Zhao, Xingwang
    Li, Yilin
    Hu, Yajie
    Sun, Yu
    Liu, Shengde
    Zhang, Zizhen
    Li, Yanyan
    Feng, Xujiao
    Yuan, Jiajia
    Li, Jian
    Zhang, Xiaotian
    Chen, Yang
    Shen, Lin
    IUBMB LIFE, 2024, 76 (07) : 420 - 436
  • [36] HER2-positive advanced breast cancer
    Robert, Nicholas J.
    Favret, Anne M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
  • [37] Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study
    Marczyk, Vicente Rodrigues
    Rosa, Daniela Dornelles
    Maia, Ana Luiza
    Goemann, Iuri Martin
    CLINICAL BREAST CANCER, 2022, 22 (05) : 418 - 423
  • [38] HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression
    Di Cosimo, Serena
    Serpico, Danila
    Porcu, Luca
    Tessari, Anna
    Molino, Leonardo
    Torri, Valter
    de Braud, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer
    Chi, Wei-Ru
    Xiu, Bingqiu
    Xiong, Min
    Li, Pei
    Zhang, Qi
    Li, Lun
    Hou, Jianjing
    Zhou, Xujie
    Sang, Yuting
    Chen, Ming
    Zhang, Liyi
    Xue, Jingyan
    Chi, Yayun
    Wu, Jiong
    CANCER RESEARCH, 2023, 83 (05)
  • [40] EFFICACY OF HER2-TARGETED ANTIBODY THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
    Hulsbergen, Alexander
    Broekman, Marike
    Smith, Timothy
    Aizer, Ayal A.
    Iorgulescu, Bryan
    NEURO-ONCOLOGY, 2020, 22 : 131 - 131
12345